| Document |
Document Title |
|
WO/2024/008805A1 |
The invention relates to heteroaromatic ketones of formula (I) for radical and cationic polymerization (I), wherein the substituents A, B, C and D can be the same or different and are nitrogen or carbon, while R1 and R2, independently of...
|
|
WO/2024/003557A1 |
Described herein are compounds of formula I, or a salt or solvate, thereof formula (I). Also described are pharmaceutical compositions and combinations comprising the compounds, and their use in the treatment of conditions mediated by ly...
|
|
WO/2024/002457A1 |
A polyamide comprising monomer units containing at least one elementary unit according to formula (I), wherein R1 is a linear alkyl containing 1 to 6 carbon atoms; and wherein R2 is an aliphatic chain containing 1 to 30 carbon atoms sele...
|
|
WO/2023/250060A1 |
Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Dis...
|
|
WO/2023/250467A2 |
In one aspect, the present disclosure relates to compounds which inhibit one or more β-lactamases and/or penicillin binding proteins (PBPs), and pharmaceutical compositions thereof. In another aspect, the present disclosure provides a m...
|
|
WO/2023/246836A1 |
The present application relates to the technical field of biological medicines, and in particular relates to a novel five-membered heterocycle substituted styrene derivative, and a preparation method therefor and the use thereof. The sty...
|
|
WO/2023/246371A1 |
The present application discloses a small molecule compound having a pyrimidothiophene structure, and a use thereof. By means of inhibiting activity of the cyclin-dependent kinase (CDK) family, the small molecule compound can block the c...
|
|
WO/2023/247416A1 |
The present invention relates to compounds of the tetraarylbenzidine- type, bearing specific (het)aryl groups at the nitrogen atoms bound to the 1,1 '-biphenylene backbone, and to methods for their preparation. The invention further rela...
|
|
WO/2023/244599A1 |
The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use th...
|
|
WO/2023/240791A1 |
Disclosed in the present invention is an environment-friendly preparation method for an N-methylamide compound. An LED lamp is used as a light source to provide energy, an economical and easily available tertiary amide is used as a react...
|
|
WO/2023/239675A1 |
The present disclosure is related to STING agonists, pharmaceutical compositions thereof, and the use of the agonists and pharmaceutical compositions to induce a STING-mediated immune response and/or to treat diseases and disorders media...
|
|
WO/2023/239092A1 |
The present invention provides a novel compound and an organic light emitting device using same.
|
|
WO/2023/239500A1 |
Systems and methods are provided for integrated production of both thiophene (and/or substituted thiophenes) and carbon nanotubes. The product effluent from thiophene synthesis can include thiophene, a sulfur-containing organic compound,...
|
|
WO/2023/239091A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2023/238629A1 |
The present disclosure provides an organic compound characterized by being represented by general formula [1]. In general formula [1], Ar1 and Ar2 are each independently selected from among an aryl group and a heterocyclic group. Ar1 and...
|
|
WO/2023/237073A1 |
The present invention relates to an organic compound comprising an aromatic amine, and the use thereof in an organic electronic device. The organic compound according to the present invention has a relatively high thermal stability, wher...
|
|
WO/2023/234603A1 |
The present invention relates to an organic compound employed in an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting device. The organic compound according to the present invention...
|
|
WO/2023/227697A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...
|
|
WO/2023/227676A1 |
The present invention relates to the use of malonic acid monoamides and malonamide esters of the formula (I) wherein the variables are as defined in the claims and the description, for controlling unwanted vegetation, to a method for com...
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/222909A1 |
The inventors have now succeeded in developing arylsulfonium salts, in particular triarylsulfonium salts and dibenzothiophenium salts and a new use of said arylsulfonium salts. These compounds have the advantage of having a thioaryl grou...
|
|
WO/2023/222850A1 |
The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tr...
|
|
WO/2023/218933A1 |
The present invention addresses the problem of providing a photoelectric conversion element which has excellent quantum efficiency when receiving blue light, an imaging element, a photosensor, and a compound. This photoelectric conversio...
|
|
WO/2023/215279A1 |
The invention relates to the unexpected discovery that the oral administration of charged sodium channel blockers, also called "Nocions," alleviates inflammation in intestinal inflammatory diseases, such as inflammatory bowel disease (IB...
|
|
WO/2023/214935A1 |
The present disclosure provides improved processes for the preparation of Relugolix and intermediates thereof. Relugolix is prepared via intermediates (M7) and (M8):, wherein X is as described herein. Present disclosure also provides thr...
|
|
WO/2023/210772A1 |
A first problem to be addressed by the present invention is to provide a photoelectric conversion element that has excellent quantum efficiency when receiving blue light. A second problem to be addressed by the present invention is to pr...
|
|
WO/2023/211940A1 |
The present disclosure provides STING agonists, and compositions, formulations. and methods for treating diseases or disorders (e.g., cancer, inflammatory diseases, autoimmune diseases, and infectious diseases) with the STING agonists or...
|
|
WO/2023/211930A1 |
The present disclosure provides dual functioning compounds, compositions, formulations, and methods for inducing or modulating an immune or inflammatory response and treating diseases or disorders (e.g., cancer, autoimmune diseases, infl...
|
|
WO/2023/206835A1 |
The present invention belongs to the technical field of catalyst preparation, and discloses a cross-linked norbornene copolymer/carbon black three-dimensional network immobilized bimetallic copper/gold nano-catalyst, and a preparation me...
|
|
WO/2023/202377A1 |
The present application provides a deuterated composition, an organic electroluminescent device, and a display apparatus. The deuterated composition comprises a deuterated mixture prepared from compound A by means of a deuteration reacti...
|
|
WO/2023/202582A1 |
A compound of a GPR132 regulator, a pharmaceutically acceptable salt or ester, a prodrug, a stereoisomer, a hydrate, a solvate, a crystal form, or a metabolite form thereof, as well as a preparation method therefor and medicinal use ther...
|
|
WO/2023/202198A1 |
The present application relates to an organic material, an electronic element, and an electronic apparatus. The organic material provided by the present application has a structure as shown in formula 1. The organic material is applied t...
|
|
WO/2023/202578A1 |
The present invention relates to a GPCR regulator and use thereof, and particularly provides a compound represented by formula (I), or a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt, a pharmaceutically acce...
|
|
WO/2023/200196A1 |
The present invention relates to an organic compound employed in an organic layer in an organic light-emitting device, such as a hole transport layer and an electron blocking layer. The organic compound according to the present invention...
|
|
WO/2023/200195A1 |
The present invention relates to an organic compound, which is employed for an organic layer, such as a hole transport layer or an electron block layer, of an organic light emitting diode. The organic compound according to the present in...
|
|
WO/2023/200226A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device including the compound.
|
|
WO/2023/200225A1 |
The present specification provides a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2023/199851A1 |
Provided are: a semiconductor substrate manufacturing method using a resist underlayer film-forming composition from which it is possible to form a film having excellent etching resistance, heat resistance, and bending resistance; a comp...
|
|
WO/2023/195791A1 |
The present invention relates to a phenylpropenone backbone compound, which is a novel chromanone or a ring-opened form thereof, and a composition for preventing or treating multiple myeloma comprising same as an active ingredient. The c...
|
|
WO/2023/193101A1 |
Antibacterial and or adjuvant compounds or pharmaceutically acceptable salts thereof according to Formula (I) are provided. Formula (I) in which R1-6 have the meanings described herein. Other methods of use are also provided.
|
|
WO/2023/190987A1 |
Provided are: a compound represented by either formula (1) or formula (2) (where the symbols in formula (1) and formula (2) are as defined in the description); an organic electroluminescent element containing the compound; and an electro...
|
|
WO/2023/171670A1 |
This resist composition, which generates an acid by being exposed to light and of which the solubility in a developer changes due to the action of the acid, contains a resin component (A1) of which the solubility in a developer changes d...
|
|
WO/2023/171788A1 |
The present invention addresses the problem of providing: a photoelectric conversion element which is excellent in production applicability and also excellent in photoelectric conversion efficiency; an imaging element; a photosensor; and...
|
|
WO/2023/169456A1 |
This disclosure relates to GLP-1 agonists, pharmaceutical compositions, and methods of use thereof.
|
|
WO/2023/172818A1 |
The present disclosure provides polymorphs of 3-(2,3,5,6-tetrafluoro-3'-trifluoromethoxy-biphenyl-4-ylcarb
amoyl)-thiophene-2-carboxylic acid, and methods of making such polymorphs. The present disclosure further provides pharmaceutical ...
|
|
WO/2023/166203A1 |
The present invention relates to GPR120 agonists for use in the treatment of inflammatory bowel disease, in particular ulcerative colitis or Crohn's disease.
|
|
WO/2023/160121A1 |
The present application belongs to the technical field of organic materials. Provided are an organic compound, an electronic element comprising same, and an electronic device, wherein the organic compound has a structure as represented b...
|
|
WO/2023/162907A1 |
This resist composition includes a base component (A) and a compound (B0) represented by general formula (b0). In the formula, Ar0 is an arylene group or a hetero arylene group. Rm1 and Rm2 are substituents other than an iodine atom. L01...
|
|
WO/2023/159303A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatmen...
|
|
WO/2023/157862A1 |
Provided is a method for producing α-fluoroether starting from an inactivated chloride. Disclosed is a method for producing a compound represented by formula (3), the method comprising step A in which a compound represented by formula (...
|
